Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You 3 Undervalued Names Too Cheap to IgnoreAuthored by Nathan Reiff. Article Published: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: Elon's "Hidden" Company
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below all represent potential value plays, with value metrics that are historically low and/or competitive relative to peers or the broader market. They offer added benefits such as compelling dividends or promising new product developments. While value opportunities may be harder to find when many high-growth companies are back in favor—or when apparent bargains have deteriorating operations—well-established, stable names can still present attractive value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works ChatGPT's TRILLION Dollar IPO (Announcement March 18?) Most regular investors are locked out of Pre-IPO investing. But for $100... You can get Pre-IPO Exposure to ChatGPT. Click Here for FREE Ticker Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co., Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45, well below the medical-industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year, and it has about 5% of additional upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda. The European Commission approved a subcutaneous formulation in late 2025, and the drug reached about $8.4 billion in sales in Q4 2025, an increase of almost 7% year-over-year (YOY). Keytruda also shows promise in ovarian cancer, potentially expanding its patient base. That should help Merck continue to build revenue as it prepares for Keytruda's expected loss of patent exclusivity in 2028. Merck's portfolio is broadening beyond oncology. The company recently announced notable phase 3 results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health business into two units to facilitate growth in non-cancer drug sales as it plans for Keytruda's eventual patent expiration. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell’s (NASDAQ: CPB) shares have fallen about 37% over the past year as the food-and-beverage staple contends with tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest YOY declines in organic net sales and consumption, and adjusted earnings per share (EPS) fell 13% over the same period. Margin improvement has been limited so far, even after cost-saving measures were initiated. The near term will likely remain challenging for the iconic brand, as fiscal-year guidance is weak overall. Still, Campbell's improving supply chain and strong brand loyalty—especially for its premium offerings—should help protect the business. A shifting tariff landscape could also ease some pressure. Additionally, Campbell's remains an attractive dividend play, with an impressive yield of 5.9%, although its payout ratio is fairly high at more than 80%. Its P/E ratio of 13.5 is the lowest in roughly four years. These factors may persuade some investors that the stock is worth considering, despite Wall Street caution. A Recent US Foods Rally May Continue, and Bottom-Line Growth Remains in Place Foodservice-distribution leader US Foods (NYSE: USFD) has had an opposite trajectory to Campbell's—shares have climbed about 33% in the last year. Even after the rally, its P/E ratio of 31.6 remains reasonable relative to some peers. On the fundamentals, US Foods is making meaningful strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% YOY. Better inventory management and cost-of-goods savings are helping the firm gain traction. With a $4 billion capital deployment plan, US Foods is well-positioned to sustain revenue growth and continue improving adjusted EBITDA. Analysts rate USFD as a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
| 
